Roche

The Food and Drug Administration is warning doctors about another counterfeit version of the cancer drug Avastin distributed in the U.S., the third case involving the best-selling Roche drug in the past year.

The Food and Drug Administration is warning doctors about another counterfeit version of the cancer drug Avastin distributed in the U.S., the third case involving the best-selling Roche drug in the past year.

Today Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the use of its PCR based mycoplasma detection test MycoTOOL for release testing of one of Roche's biological products. It is the first commercially available mycoplasma PCR test accepted by the FDA for release testing of a biopharmaceutical product that can replace conventional and time-consuming mycoplasma detection assays based on culture methods.

Mayor Greg Ballard today joined Roche Diagnostics President and CEO Jack Phillips as well as other Roche executives and community leaders to break ground on the company's new Learning and Development Center. The center is the first element of a $300 million site transformation investment that was announced in June 2012. The city of Indianapolis and the Indiana Economic Development Corporation offered Roche tax abatements, tax credits and training grants to support Roche's investment.

Co-cultivation can be used in a wide variety of applications, including cell signalling and toxicology testing. A key goal in drug discovery is to identify how to most effectively monitor cell-cell interactions when cells show pathology. Roche Applied Science is now providing the new E-Plate Insert 16 and E-Plate Insert 96, permitting continual impedance-based monitoring of indirect cell-cell interactions/communication using xCELLigence Instruments.

Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy

A new batch of counterfeit Avastin discovered in the United States was shipped from

[PR Newswire]
Published Date: November 22, 2011 04:05:00 PM EST
 

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: